Skip to main content
SpringerLink
Log in

Wenn die Beine nicht mehr zur Ruhe kommen

Restless-Legs-Syndrom

  • Fortbildung
  • Published:
DNP - Der Neurologe und Psychiater Aims and scope

Zusammenfassung

Das Restless-Legs-Syndrom ist eine chronisch-progrediente Erkrankung mit sehr variabler klinischer Ausprägung von milden, intermittierenden und wenig belastenden Symptomen bis hin zu täglichen Beschwerden mit erheblichen Ein- und Durchschlafstörungen. Abhängig von der Ausprägung des Schweregrades benötigt aber nur ein kleiner Teil aller RLS-Patienten eine medikamentöse Therapie.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Berger K, Luedemann J, Trenkwalder C, John U, Kessler C. Sex and the risk of restless legs syndrome in the general population. Archives of internal medicine. 2004;164(2):196–202.

    Article  PubMed  Google Scholar 

  2. Rothdach AJ, Trenkwalder C, Haberstock J, Keil U, Berger K. Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly. Neurology. 2000;54(5):1064–8.

    Article  CAS  PubMed  Google Scholar 

  3. Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, et al. Restless legs syndrome prevalence and impact: REST general population study. Archives of internal medicine. 2005;165(11):1286–92.

    Article  PubMed  Google Scholar 

  4. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep medicine. 2003;4(2):101–19.

    Article  PubMed  Google Scholar 

  5. Stiasny-Kolster K, Kohnen R, Moller JC, Trenkwalder C, Oertel WH. Validation of the „L-DOPA test“ for diagnosis of restless legs syndrome. Movement disorders: official journal of the Movement Disorder Society. 2006;21(9):1333–9.

    Article  Google Scholar 

  6. Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Movement disorders: official journal of the Movement Disorder Society. 1997;12(1):61–5.

    Article  CAS  Google Scholar 

  7. Schormair B, Kemlink D, Roeske D, Eckstein G, Xiong L, Lichtner P, et al. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nature genetics. 2008;40(8):946–8.

    Article  CAS  PubMed  Google Scholar 

  8. Winkelmann J, Schormair B, Lichtner P, Ripke S, Xiong L, Jalilzadeh S, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nature genetics. 2007;39(8):1000–6.

    Article  CAS  PubMed  Google Scholar 

  9. Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep medicine. 2003;4(2):121–32.

    Article  PubMed  Google Scholar 

  10. Silber MH, Ehrenberg BL, Allen RP, Buchfuhrer MJ, Earley CJ, Hening WA, et al. An algorithm for the management of restless legs syndrome. Mayo Clinic proceedings Mayo Clinic. 2004;79(7):916–22.

    Article  Google Scholar 

  11. Allen R, Becker PM, Bogan R, Schmidt M, Kushida CA, Fry JM, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep. 2004;27(5):907–14.

    PubMed  Google Scholar 

  12. Inoue YI, Hirata K, Kuroda K, Fujita M, Shimizu T, Emura N, et al. Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome: A polysomnographic randomized, double-blind, placebo-controlled study. Sleep Med. 2010 Jan;11(1):11–6.

    Article  PubMed  Google Scholar 

  13. Oertel WH, Benes H, Garcia-Borreguero D, Hogl B, Poewe W, Montagna P, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep medicine. 2010;11(9):848–56.

    Article  PubMed  Google Scholar 

  14. Inoue Y, Kuroda K, Hirata K, Uchimura N, Kagimura T, Shimizu T. Long-term open-label study of pramipexole in patients with primary restless legs syndrome. Journal of the neurological sciences. 2010;294(1–2):62–6.

    Article  CAS  PubMed  Google Scholar 

  15. Garcia-Borreguero D, Hogl B, Ferini-Strambi L, Winkelman J, Hill-Zabala C, Asgharian A, et al. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Movement disorders: official journal of the Movement Disorder Society. 2012;27(2):277–83.

    Article  CAS  Google Scholar 

  16. Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, O’Keeffe S, Trenkwalder C, Hogl B, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. European journal of neurology: the official journal of the European Federation of Neurological Societies. 2012;19(11):1385–96.

    Article  Google Scholar 

  17. Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M. Levodopa for restless legs syndrome. The Cochrane database of systematic reviews. 2011(2):CD005504.

  18. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996;19(3):205–13.

    CAS  PubMed  Google Scholar 

  19. Hogl B, Garcia-Borreguero D, Kohnen R, Ferini-Strambi L, Hadjigeorgiou G, Hornyak M, et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. Journal of neurology. 2010;257(2):230–7.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Oertel W, Trenkwalder C, Benes H, Ferini-Strambi L, Hogl B, Poewe W, et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet neurology. 2011;10(8):710–20.

    Article  CAS  PubMed  Google Scholar 

  21. Silver N, Allen RP, Senerth J, Earley CJ. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep medicine. 2011;12(5):440–4.

    Article  PubMed  Google Scholar 

  22. Lauerma H, Markkula J. Treatment of restless legs syndrome with tramadol: an open study. The Journal of clinical psychiatry. 1999;60(4):241–4.

    Article  CAS  PubMed  Google Scholar 

  23. Trenkwalder C, Benes H, Grote L, Garcia-Borreguero D, Hogl B, Hopp M, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet neurology. 2013;12(12):1141–50.

    Article  CAS  PubMed  Google Scholar 

  24. Walters AS, Wagner ML, Hening WA, Grasing K, Mills R, Chokroverty S, et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep. 1993;16(4):327–32.

    CAS  PubMed  Google Scholar 

  25. Walters AS, Winkelmann J, Trenkwalder C, Fry JM, Kataria V, Wagner M, et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Movement disorders: official journal of the Movement Disorder Society. 2001;16(6):1105–9.

    Article  CAS  Google Scholar 

  26. Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology. 2002;59(10):1573–9.

    Article  CAS  PubMed  Google Scholar 

  27. Happe S, Sauter C, Klosch G, Saletu B, Zeitlhofer J. Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology. 2003;48(2):82–6.

    Article  CAS  PubMed  Google Scholar 

  28. Allen R, Chen C, Soaita A, Wohlberg C, Knapp L, Peterson BT, et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep medicine. 2010;11(6):512–9.

    Article  PubMed  Google Scholar 

  29. Garcia-Borreguero D, Larrosa O, Williams AM, Albares J, Pascual M, Palacios JC, et al. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology. 2010;74(23):1897–904.

    Article  CAS  PubMed  Google Scholar 

  30. Burke RA, Faulkner MA. Review of the treatment of restless legs syndrome: focus on gabapentin enacarbil. Journal of central nervous system disease. 2012;4:147–56.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Ellenbogen AL, Thein SG, Winslow DH, Becker PM, Tolson JM, Lassauzet ML, et al. A 52-week study of gabapentin enacarbil in restless legs syndrome. Clinical neuropharmacology. 2011;34(1):8–16.

    Article  CAS  PubMed  Google Scholar 

  32. Lal R, Ellenbogen A, Chen D, Zomorodi K, Atluri H, Luo W, et al. A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. Clinical neuropharmacology. 2012;35(4):165–73.

    Article  CAS  PubMed  Google Scholar 

  33. Winkelman JW, Bogan RK, Schmidt MH, Hudson JD, DeRossett SE, Hill-Zabala CE. Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Movement disorders: official journal of the Movement Disorder Society. 2011;26(11):2065–72.

    Article  Google Scholar 

  34. Schulte EC, Gross N, Slawik H, Winkelmann J. When restless legs syndrome turns malignant. Sleep medicine. 2013;14(6):575–7.

    Article  PubMed  Google Scholar 

  35. O’Keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age and ageing. 1994;23(3):200–3.

    Article  PubMed  Google Scholar 

  36. Sun ER, Chen CA, Ho G, Earley CJ, Allen RP. Iron and the restless legs syndrome. Sleep. 1998;21(4):371–7.

    CAS  PubMed  Google Scholar 

  37. Frauscher B, Gschliesser V, Brandauer E, El-Demerdash E, Kaneider M, Rucker L, et al. The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels. Sleep medicine. 2009;10(6):611–5.

    Article  PubMed  Google Scholar 

  38. Trenkwalder C, Hogl B, Benes H, Kohnen R. Augmentation in restless legs syndrome is associated with low ferritin. Sleep medicine. 2008;9(5):572–4.

    Article  PubMed  Google Scholar 

  39. Leitlinien Restless Legs Syndrom (RLS) und Periodic Limb Movement Disorder (PLMD). Entwicklungsstufe S1, Stand September 2012. AWMF-Registernummer 030/081

  40. Earley CJ, Heckler D, Allen RP. The treatment of restless legs syndrome with intravenous iron dextran. Sleep medicine. 2004;5(3):231–5.

    Article  PubMed  Google Scholar 

  41. Earley CJ, Heckler D, Allen RP. Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome. Sleep medicine. 2005;6(4):301–5.

    Article  PubMed  Google Scholar 

  42. Ondo WG. Intravenous iron dextran for severe refractory restless legs syndrome. Sleep medicine. 2010;11(5):494–6.

    Article  PubMed  Google Scholar 

  43. Auerbach M. Finding a safe and effective intravenous iron treatment for restless legs syndrome. Sleep medicine. 2010;11(5):429–30.

    Article  PubMed  Google Scholar 

  44. Grote L, Leissner L, Hedner J, Ulfberg J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement disorders: official journal of the Movement Disorder Society. 2009;24(10):1445–52.

    Article  Google Scholar 

  45. Earley CJ, Horska A, Mohamed MA, Barker PB, Beard JL, Allen RP. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep medicine. 2009;10(2):206–11.

    Article  PubMed Central  PubMed  Google Scholar 

  46. Vadasz D, Ries V, Oertel WH. Intravenous iron sucrose for restless legs syndrome in pregnant women with low serum ferritin. Sleep medicine. 2013;14(11):1214–6.

    Article  PubMed  Google Scholar 

  47. Allen RP, Adler CH, Du W, Butcher A, Bregman DB, Earley CJ. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep medicine. 2011;12(9):906–13.

    Article  PubMed  Google Scholar 

  48. Oertel WH, Trenkwalder C, Zucconi M, Benes H, Borreguero DG, Bassetti C, et al. State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome. Movement disorders: official journal of the Movement Disorder Society. 2007;22 Suppl 18:S466–75.

    Article  Google Scholar 

  49. Manconi M, Govoni V, De Vito A, Economou NT, Cesnik E, Casetta I, et al. Restless legs syndrome and pregnancy. Neurology. 2004;63(6):1065–9.

    Article  CAS  PubMed  Google Scholar 

  50. Manconi M, Ferini-Strambi L, Hening WA. Response to Clinical Corners case (Sleep Medicine 6/2: 83-4): Pregnancy associated with daytime sleepiness and nighttime restlessness. Sleep medicine. 2005;6(5):477–8.

    Article  PubMed  Google Scholar 

  51. Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso T, et al. Maternal treatment with opioid analgesics and risk for birth defects. American journal of obstetrics and gynecology. 2011;204(4):314 e1–11.

    Article  PubMed  Google Scholar 

  52. Djokanovic N, Garcia-Bournissen F, Koren G. Medications for restless legs syndrome in pregnancy. Journal of obstetrics and gynaecology Canada: JOGC = Journal d’obstetrique et gynecologie du Canada: JOGC. 2008;30(6):505–7.

    PubMed  Google Scholar 

  53. Saletu M, Anderer P, Saletu-Zyhlarz G, Prause W, Semler B, Zoghlami A, et al. Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebo-controlled sleep laboratory studies with clonazepam. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. 2001;11(2):153–61.

    Article  CAS  Google Scholar 

  54. Hurault-Delarue C, Montastruc JL, Beau AB, Lacroix I, Damase-Michel C. Pregnancy outcome in women exposed to dopamine agonists during pregnancy: a pharmacoepidemiology study in EFEMERIS database. Archives of gynecology and obstetrics. 2014.

  55. Fujii H, Goel A, Bernard N, Pistelli A, Yates LM, Stephens S, et al. Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. Neurology. 2013;80(17):1565–70.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  56. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. Journal of neurology. 2014;261(3):579–88.

    Article  CAS  PubMed  Google Scholar 

  57. Merlino G, Gigli GL, Valente M. Sleep disturbances in dialysis patients. Journal of nephrology. 2008;21 Suppl 13:S66–70.

    PubMed  Google Scholar 

  58. Sloand JA, Shelly MA, Feigin A, Bernstein P, Monk RD. A double-blind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2004;43(4):663–70.

    Article  CAS  Google Scholar 

  59. Trenkwalder C, Stiasny K, Pollmacher T, Wetter T, Schwarz J, Kohnen R, et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep. 1995;18(8):681–8.

    CAS  PubMed  Google Scholar 

  60. Pellecchia MT, Vitale C, Sabatini M, Longo K, Amboni M, Bonavita V, et al. Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release. Clinical neuropharmacology. 2004;27(4):178–81.

    Article  CAS  PubMed  Google Scholar 

  61. Miranda M, Kagi M, Fabres L, Aguilera L, Alvo M, Elgueta L, et al. Pramipexole for the treatment of uremic restless legs in patients undergoing hemodialysis. Neurology. 2004;62(5):831–2.

    Article  CAS  PubMed  Google Scholar 

  62. Thorp ML, Morris CD, Bagby SP. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2001;38(1):104–8.

    Article  CAS  Google Scholar 

  63. de Oliveira MM, Conti CF, Valbuza JS, de Carvalho LB, do Prado GF. The pharmacological treatment for uremic restless legs syndrome: evidence-based review. Movement disorders: official journal of the Movement Disorder Society. 2010;25(10):1335–42.

    Article  Google Scholar 

  64. Winkelmann J, Stautner A, Samtleben W, Trenkwalder C. Long-term course of restless legs syndrome in dialysis patients after kidney transplantation. Movement disorders: official journal of the Movement Disorder Society. 2002;17(5):1072–6.

    Article  Google Scholar 

  65. Garcia-Borreguero D, Stillman P, Benes H, Buschmann H, Chaudhuri KR, Gonzalez Rodriguez VM, et al. Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC neurology. 2011;11:28.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinikum rechts der Isar der Technischen Universität München Neurologische Klinik und Poliklinik im Neuro-Kopf-Zentrum, Ismaninger Str. 22, 81675, München, Deutschland

    Juliane Winkelmann &  Nadine Groß

Authors
  1. Juliane Winkelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nadine Groß
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juliane Winkelmann.

Additional information

Interessenkonflikt

Die Autorinnen erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Prof. Winkelmann erklärt den Erhalt von Forschungsgeldern von UCB, Beratungstätigkeit für Mundipharma, für eine Studie die Eisen bei RLS untersucht (Vifor), und ist im Advisory Board von UCB. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Winkelmann, J., Groß, N. Wenn die Beine nicht mehr zur Ruhe kommen. DNP 15, 53–65 (2014). https://doi.org/10.1007/s15202-014-0715-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15202-014-0715-z

Search

Navigation